Want to see GB:EAH full AI Analyst Report?
Top Page
Eco Animal Health
(LSE:EAH)
Select Model
Select Model
Rating:66Neutral
Price Target:
109.00 p
▲(7.92% Upside)
Action:Reiterated
Date:07/25/26
The score is driven primarily by improving fundamentals backed by a very low-leverage balance sheet and positive recent cash generation. Offsetting this, profitability and cash-flow consistency have been volatile over multiple years, technical momentum is mixed (negative MACD despite price strength), and valuation looks demanding at ~28x earnings.
Positive Factors
Low leverage / strong balance sheet
A very low debt-to-equity position (debt ~£4.9m vs equity ~£87.1m) provides durable financial flexibility. This conservative balance sheet supports funding regulatory approvals, commercial expansion, and absorbing demand shocks without relying on costly external financing over the medium term.
Negative Factors
Volatile cash flows historically
Historical swings in operating and free cash flow, including negative results in FY2022, indicate inconsistent cash conversion. This variability undermines confidence in funding timing for regulatory spend and commercial investment and raises execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
A very low debt-to-equity position (debt ~£4.9m vs equity ~£87.1m) provides durable financial flexibility. This conservative balance sheet supports funding regulatory approvals, commercial expansion, and absorbing demand shocks without relying on costly external financing over the medium term.
Read all positive factors
Eco Animal Health (EAH) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£65.73M
Dividend YieldN/A
Average Volume (3M)75.04K
Price to Earnings (P/E)31.0
Beta (1Y)0.69
Revenue Growth9.96%
EPS Growth29.72%
CountryUK
Employees227
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.03
Shares Outstanding67,759,674
10 Day Avg. Volume57,390
30 Day Avg. Volume75,042
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)0.74
Price to Sales (P/S)0.74
P/FCF Ratio8.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)£88.21M
Eco Animal Health Business Overview & Revenue Model
Company Description
ECO Animal Health Group plc, established in 1972 and based in New Malden, United Kingdom, focuses on the worldwide research, regulatory approval, and distribution of veterinary pharmaceutical solutions. The company's offerings include Aivlosin, a ...
How the Company Makes Money
EAH makes money primarily by selling animal health products into veterinary and livestock markets. Its revenue model combines (1) sales of its own branded veterinary pharmaceutical products (where EAH develops/owns and commercializes specific prod...
Eco Animal Health Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
86
Very Positive
Cash Flow
67
Positive
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 87.53M | 79.60M | 89.42M | 85.31M | 82.19M |
| Gross Profit | 42.50M | 35.91M | 37.68M | 36.75M | 33.70M |
| EBITDA | 8.06M | 7.29M | 6.53M | 7.41M | 3.62M |
| Net Income | 2.19M | 1.69M | 1.05M | 1.01M | -686.00K |
Balance Sheet | |||||
| Total Assets | 118.56M | 120.60M | 123.27M | 121.31M | 113.60M |
| Cash, Cash Equivalents and Short-Term Investments | 25.43M | 25.01M | 22.37M | 21.66M | 14.31M |
| Total Debt | 4.93M | 3.79M | 4.03M | 4.48M | 1.91M |
| Total Liabilities | 23.05M | 25.84M | 29.89M | 25.76M | 19.25M |
| Stockholders Equity | 87.09M | 85.50M | 83.69M | 83.27M | 82.06M |
Cash Flow | |||||
| Free Cash Flow | 7.54M | 5.44M | 4.79M | 10.03M | -3.25M |
| Operating Cash Flow | 7.73M | 10.45M | 9.42M | 16.01M | -358.00K |
| Investing Cash Flow | -3.78M | -4.61M | -3.42M | -5.98M | -2.88M |
| Financing Cash Flow | -4.21M | -1.95M | -3.69M | -2.40M | -3.31M |
Eco Animal Health Technical Analysis
Positive
101.00
Price Trends
91.93
Positive
94.10
Positive
96.74
Positive
Market Momentum
0.20
Negative
72.78
Negative
75.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EAH, the sentiment is Positive. The current price of 101 is above the 20-day moving average (MA) of 91.45, above the 50-day MA of 91.93, and above the 200-day MA of 96.74, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 72.78 is Negative, neither overbought nor oversold. The STOCH value of 75.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:EAH.
Eco Animal Health Peers Comparison
UnderperformOutperform
Sector (51)
GB:EAH
Eco Animal Health
100.00
25.50
34.23%
GB:ANCR
Animalcare
335.00
67.57
25.27%
Eco Animal Health Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
ECO Animal Health CEO Increases Stake as Vaccine Strategy Advances
Positive
Jul 16, 2026
ECO Animal Health Group reported that Chief Executive Officer David Hallas purchased 22,346 ordinary shares at 89.5 pence each on 16 July, increasing his holding to 225,387 shares, or about 0.33% of the company’s issued share capital. The on...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
ECO Animal Health Beats Expectations as Vaccine Strategy Takes Hold
Positive
Jul 15, 2026
ECO Animal Health reported a robust FY26 performance, with revenue rising 10% to £87.5m and adjusted EBITDA up 16% to £8.5m, both ahead of market expectations. Strong growth in North America and Latin America, improved pricing and mix, a...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Eco Animal Health Sets July Dates for Annual Results and Investor Briefings
Positive
Jul 13, 2026
Eco Animal Health Group plc, a UK-based global veterinary pharmaceuticals company, specialises in branded treatments that enhance livestock health and productivity, led by its flagship antibiotic Aivlosin for pigs and poultry. The business is broa...
Business Operations and StrategyProduct-Related Announcements
Eco Animal Health launches first proprietary poultry vaccine across EU
Positive
Jul 2, 2026
Eco Animal Health has launched ECOVAXXIN MS, a vaccine targeting Mycoplasma synoviae infections in poultry, across the European Union, marking the first product from its proprietary RD pipeline to reach commercialisation. The vaccine is designed t...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Eco Animal Health Secures Long-Term £15m Banking Facilities on Better Terms
Positive
Jun 4, 2026
Eco Animal Health Group has renewed its £10 million committed revolving credit facility with NatWest on improved terms, alongside a renewed £5 million overdraft, maintaining total banking facilities of £15 million through to 30 June...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.